Tarsus Pharmaceuticals, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
175.34 |
399.88 |
576.38 |
790.57 |
841.83 |
966.37 |
| Przychód Δ r/r |
0.00% |
128.06% |
44.14% |
37.16% |
6.48% |
14.79% |
| Przychód (min) |
171.31 |
371.44 |
424.91 |
777.38 |
702.11 |
805.99 |
| Przychód (max) |
181.03 |
422.20 |
711.43 |
803.77 |
961.36 |
1,103.59 |
| EBITDA (średnia) |
-63.57 |
-144.99 |
-208.98 |
-286.64 |
-305.23 |
-350.38 |
| EBIT (średnia) |
-64.18 |
-146.37 |
-210.98 |
-289.38 |
-308.14 |
-353.73 |
| EBIT % |
-36.60% |
-36.60% |
-36.60% |
-36.60% |
-36.60% |
-36.60% |
| Zysk netto (średni) |
-120.63 |
-46.16 |
41.83 |
216.83 |
189.90 |
238.41 |
| Zysk netto % |
-68.80% |
-11.54% |
7.26% |
27.43% |
22.56% |
24.67% |
| EPS (średnia) |
-3.22 |
-1.23 |
0.94 |
4.21 |
5.05 |
6.34 |
| Liczba analityków (Przychody) |
6 |
5 |
6 |
4 |
2 |
3 |
| Liczba analityków (EPS) |
5 |
4 |
4 |
4 |
3 |
2 |
| symbol |
TARS |
TARS |
TARS |
TARS |
TARS |
TARS |